trial

Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids

NCTId NCT00211562
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Terminated
Enrollment 20 (actual)
Sponsored by Augusta University
Primary completion 2006-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Terminated
Enrollment
20 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2005-10
Primary completion
2006-01
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Olanzapine

Sponsors

Augusta UniversityLead Sponsor
Eli Lilly and CompanyCollaborator
Medical Service Line ABRCCollaborator
US Department of Veterans AffairsCollaborator

Investigators

1
Peter Handest, MD, Ph.d.Principal Investigator

Sites

1 total
Augusta, United States

Linked catalysts

1
Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty A — primary completion2006-01

Facts & assertions

4 sourced
Enrollment
20
Phase
PHASE3
Primary Completion Date
2006-01
Status
TERMINATED
relationships
The graph out of here
drug
Olanzapine
drug
lead_sponsor
Augusta University
company
collaborator
Eli Lilly and Company
company
Medical Service Line ABRC
company
indication
Schizophrenia
indication
Schizophrenia
indication
Weight Gain
indication
investigator
Peter Handest, MD, Ph.d.
person